239 related articles for article (PubMed ID: 19889174)
1. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients.
Rüping MJ; Müller C; Vehreschild JJ; Böhme A; Mousset S; Harnischmacher U; Frommolt P; Wassmer G; Drzisga I; Hallek M; Cornely OA
Mycoses; 2011 May; 54(3):230-3. PubMed ID: 19889174
[TBL] [Abstract][Full Text] [Related]
2. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
4. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
6. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation.
Groll AH; Kolve H; Ehlert K; Paulussen M; Vormoor J
J Antimicrob Chemother; 2004 Jan; 53(1):113-4. PubMed ID: 14657088
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients.
Gómez-López A; Cendejas-Bueno E; Cuesta I; García Rodríguez J; Rodríguez-Tudela JL; Gutiérrez-Altés A; Cuenca-Estrella M
Med Mycol; 2012 May; 50(4):439-45. PubMed ID: 22070341
[TBL] [Abstract][Full Text] [Related]
10. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V
Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382
[TBL] [Abstract][Full Text] [Related]
14. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.
Miyakis S; van Hal SJ; Solvag CJ; Ray J; Marriott D
Ther Drug Monit; 2010 Oct; 32(5):661-4. PubMed ID: 20720520
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
Pieper S; Kolve H; Gumbinger HG; Goletz G; Würthwein G; Groll AH
J Antimicrob Chemother; 2012 Nov; 67(11):2717-24. PubMed ID: 22796890
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration.
Radej J; Krouzecky A; Stehlik P; Sykora R; Chvojka J; Karvunidis T; Novak I; Matejovic M
Ther Drug Monit; 2011 Aug; 33(4):393-7. PubMed ID: 21654349
[TBL] [Abstract][Full Text] [Related]
17. [Level of evidence for therapeutic drug monitoring of voriconazole].
Hulin A; Dailly E; Le Guellec C;
Therapie; 2011; 66(2):109-14. PubMed ID: 21635857
[TBL] [Abstract][Full Text] [Related]
18. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole-associated severe hyponatremia.
Kim KH; Lee S; Lee S; Yun NR; Kim NJ; Yu KS; Jang IJ; Park WB; Oh MD
Med Mycol; 2012 Jan; 50(1):103-5. PubMed ID: 21671829
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
